In-vitro cytochrome P450 dependent metabolism of oxybutynin to N- deethyloxybutynin in humans

Pharmacogenetics

Volumn 8, Issue 5, 1998, Pages 449-451

  Yaïch, Mansour ^a   Popon, Michel ^a   Médard, Yves ^a   Aigrain, Evelyne Jacqz ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

CYP2C19; CYP2D6; CYP2E1; CYP3A4; Cytochrome P650; Genetic polymorphism; Microsomes; Oxybutynin metabolism

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; DRUG METABOLITE; N DEETHYLOXYBUTYNIN; OXYBUTYNIN; UNCLASSIFIED DRUG;

ARTICLE; DNA POLYMORPHISM; DRUG INDUCED DISEASE; DRUG METABOLISM; ENZYME ASSAY; GENETIC RECOMBINATION; GENOTYPE; HUMAN; HUMAN CELL; LIVER METABOLISM; LIVER MICROSOME; OXIDATION; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; CHOLINERGIC ANTAGONISTS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MANDELIC ACIDS; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC;

EID: 0031668459     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199810000-00010     Document Type: Article

References (10)

1. Broly F, Gaedigk A, Heim M, Eichelbaum M, Moroke K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a european population. DNA Cell Biol 1991; 10:545-558.
2. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzales FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
3. Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, Herchuelz A. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1988; 35:515-520.
4. Duclos Vallée JC, Hajoui O, Yamamoto AM, Jacqz Aigrain E, Alvarez F. Conformational epitopes on CYP2D6 are recognized by liver/kidney microsomal antibodies. Gastroenterology 1995; 25:312-313.
5. Fredericks CM, Anderson GF, Kreulen DJ. A study of the anticholinergic and antispasmodic activity of oxybutynin (Ditropan®) on rabbit detrusor. Invest Urol 1975; 12:317-319.
6. Jonville AP, Dutertre JP, Autret E, Barbellion M. Effets indésirables du chlorure d'oxybutinine (Ditropan®). Bilan de l'enquète officielle des centres régionaux de pharmacovigilance. Thérapie 1992; 47:389-392.
7. Lindeke B, Brotell H, Karlen B, Rietz G, Vietorisz A. Determination of oxybutynin (4-diethylaminobut-2-ynyl2-cyclohexyl-2-phenylglycolate) in serum and urine by gas chromatography/mass spectrometry with single ion detection. Acta Pharm Suec 1981; 18:25-34.
8. Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. Eur J Clin Pharmacol 1997; 52:403-406.
9. Schueltz JD, Beach DL, Guzzelian PS. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 1994; 4:11-20.
10. Takai S, Matsuda A, Usami Y, Adachi T, Sugiyama T, Katagiri Y, et al. Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.5 and 4.5 from human liver. Biol Pharm Bull 1997; 20:869-873.